The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime? Michael A. Postow, Margaret K. Callahan, and Jedd D. Wolchok
See article p. 2039

Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib Augusto Villanueva and Josep M. Llovet
See article p. 2090

In Search of a Real "Targeted" Therapy for Thyroid Cancer Marcia S. Brose
See article p. 2056

New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy Mei Dong, Alexandria T. Phan, and James C. Yao

Statistical Issues and Recommendations for Noninferiority Trials in Oncology: A Systematic Review Shiro Tanaka, Yousuke Kinjo, Yoshiki Kataoka, Kenichi Yoshimura, and Satoshi Teramukai

Abiraterone in Prostate Cancer: A New Angle to an Old Problem Mark N. Stein, Susan Goodin, and Robert S. DiPaola


Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors Carlo Visco, Francesco Maura, Giacomo Tuana, Luca Agnelli, Marta Lionetti, Sonia Fabris, Elisabetta Novella, Ilaria Giaretti, Giani Luigi Reda, Wilma Barcellini, Luca Baldini, Antonino Neri, Francesco Rodeghiero, and Agostino Corteazzi

MAPKAP Kinase 2 Overexpression Influences Prognosis in Gastrointestinal Stromal Tumors and Associates with Copy Number Variations on Chromosome 1 and Expression of p58 MAP Kinase and ET1
Peter Birner, Andrea Beer, Ursula Vinatzer, Susanne Stary, Romana Höfberger, Nadine Nirtl, Fritz Wrb, Berthold Streubel, and Sebastian F. Schoppmann

Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress-Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response Sabrina Manni, Alessandra Brancalion, Laura Quotti Tubi, Anna Colpo, Laura Pavan, Anna Cabrelle, Elisa Ave, Fortunato Zaffino, Giovanni Di Maira, Maria Ruzzene, Fausto Adami, Renato Zambo, Maria Rita Pitari, Pierfrancesco Tassone, Lorenzo A. Pinna, Carmela Gurrieri, Gianpietro Semenzato, and Francesco Piazza

Glioblastoma Stem-like Cell Lines with Either Maintenance or Loss of High-Level EGFR Amplification, Generated via Modulation of Ligand Concentration Alexander Schulte, Hauke S. Gunther, Tobias Martens, Svenja Zapf, Sabine Riethdorf, Clemens Wülfling, Malgorzata Stoupiec, Manfred Westphal, and Katrin Lamszus


1936 Integrative Genomics Identified RFC3 As an Amplified Candidate Oncogene in Esophageal Adenocarcinoma William W. Lockwood, Kelsie L. Thu, Lin Lin, Larissa A. Pikor, Raj Chari, Wan L. Lam, and David G. Beer

1947 Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis Yang Zhang, Yihua Sun, Yunjian Pan, Chenguang Li, Lei Shen, Yuan Li, Xiaoyang Luo, Ting Ye, Rui Wang, Haichuan Hu, Hang Li, Lei Wang, William Pao, and Huaquan Chen

1979 ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress Colby M. Chapman, Xiaemeng Sun, Mark Roschewski, Georg Aue, Mohamed Farooqui, Lawrence Stennett, Federica Gibellini, Diane Arthur, Patricia Pérez-Galán, and Adrian Wiestner

1992 Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer Alain Mangé, Jérôme Lacombe, Caroline Bascoul-Mollevi, Marta Jarlier, Pierre-Jean Lamy, Philippe Rouanet, Thierry Maudelonde, and Jérôme Solassol

2001 Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children’s Cancer Leukaemia Group (CCLG), Société Française d’Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP) John-Paul Kilday, Biswaroop Mitra, Caroline Domerg, Jennifer Ward, Felipe Andreiuolo, Teresa Osteo-Ibanez, Audrey Mauguen, Pascale Varlet, Marie-Cécile Le Deley, James Lowe, David W. Ellison, Richard J. Gilbertson, Beth Coyle, Jacques Grill, and Richard G. Grundy

2012 A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma Idofia Garcia, Gemma Mayol, José Rios, Gema Domenech, Nai-Kong V. Cheung, André Oberthuer, Matthias Fischer, John M. Maris, Garrett M. Brodeur, Barbara Hero, Eva Rodríguez, Mariona Suñol, Patricia Galvan, Carmen de Torres, Jaume Mora, and Cinzia Lavarino

2024 18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy Ken Herrmann, Matthias R. Benz, Johannes Czernin, Martin S. Allen-Auerbach, William D. Tap, Sarah M. Dry, Tibor Schuster, Jeff J. Eckardt, Michael E. Phelps, Wolfgang A. Weber, and Fritz C. Eilber
A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration
Xavier M. Keutgen, Filippo Filicori, Michael J. Crowley, Yongchun Wang, Theresa Scognamiglio, Rana Hoda, Daniel Buitrago, David Cooper, Martha A. Zeiger, Rasa Zarnegar, Olivier Elemento, and Thomas J. Fahey III

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
Eleni M. Karapanagiotou, Victoria Roulstone, Katie Twigger, Merced Ball, MaryAnne Tanay, Chris Nutting, Kate Newbold, Martin E. Gore, James Larkin, Konstantinos N. Syrigos, Matt Coffey, Brad Thompson, Karl Mettinger, Richard G. Vile, Hardev S. Pandha, Geoff D. Hall, Alan A. Melcher, John Chester, and Kevin J. Harrington

CANCER THERAPY: CLINICAL

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto, James C. Yang, Richard M. Sherry, Marybeth S. Hughes, Uday S. Kammula, Donald E. White, Catherine L. Levy, Steven A. Rosenberg, and Giao Q. Phan
See commentary p. 1821

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer
Wen Wee Ma, Wells A. Messersmith, Grace K. Dy, Colin D. Weekes, Amy Whitworth, Chen Ren, Manoj Maniar, Francois Wilhelm, S. Gail Eckhardt, Alex A. Adjei, and Antonio Jimeno

Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
See commentary p. 1827

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
Cody J. Peer, Tristan M. Sissung, AeRang Kim, Lokesh Jain, Sukyung Woo, Erin R. Gardner, C. Tyler Kirkland, Sarah M. Troutman, Bevin C. English, Emily D. Richardson, Joel Feder Spielberg, David Venzon, William D. Figg

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer
Michael Milosevic, Padraig Warde, Cynthia Ménard, Peter Chung, Ants Toi, Adrian Ishkanian, Michael McLean, Melanie Pintilie, Janna Sykes, Mary Gosopardowicz, Charles Catton, Richard P. Hill, and Robert Bristow

CORRECTIONS

Correction: Molecular Imaging of TGFβ-Induced Smad2/3 Phosphorylation Reveals a Role for Receptor Tyrosine Kinases in Modulating TGFβ Signaling
ABOUT THE COVER

High-level EGFR gene amplification can be retained in glioblastoma stem-like cell lines established and propagated without recombinant EGF. In contrast, high-level amplification is lost in parallel cell lines from the same tumors established with EGF supplementation. Cell lines with high-level EGFR amplification produce highly aggressive xenograft tumors in the brains of nude mice, retaining the EGFR amplification as shown in the cover figure, whereas counterpart cell lines, lacking high-level amplification, are either nontumorigenic or grow significantly more slowly in vivo. For details, see the article by Schulte and colleagues on page 1901 of this issue.